Beta globin gene inhibition by antisense RNA transcripts

Gene Ther. 2000 Mar;7(5):438-44. doi: 10.1038/sj.gt.3301106.

Abstract

Sickle cell disease is caused by a mutation in the beta globin gene leading to hemoglobin S (Hb S) production. Several approaches have been explored to prevent Hb S polymerization in red blood cells and the symptoms associated with this disorder. To this end we tested a mammalian expression vector carrying a human beta globin antisense cDNA (pZeobetaAS) fragment in a mouse erythroleukemia cell line expressing the human gamma and beta globin genes. We observed a relative reduction in beta globin mRNA levels compared with gamma mRNA levels in the presence of pZeobetaAS. Moreover, analysis at the protein level showed an average 76% decrease in beta chains and a 517% increase in gamma chain biosynthesis. The inhibitory effect of the antisense vector on globin expression was maintained long term in culture. The expression vector pZeobetaAS was also transfected into primary erythroid progenitors to test its effects on globin genes undergoing normal developmental switching during differentiation. We observed a relative reduction of beta globin mRNA levels compared with gamma mRNA levels. These results support a novel role for antisense cDNA expression vectors as an alternative gene therapy strategy to inhibit betas gene expression in sickle cell disease. Gene Therapy (2000) 7, 438-444.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anemia, Sickle Cell / therapy
  • Animals
  • DNA, Antisense / metabolism
  • Genetic Therapy / methods
  • Genetic Vectors / genetics
  • Globins / genetics*
  • Humans
  • Leukemia, Erythroblastic, Acute
  • Mice
  • RNA, Antisense / genetics*
  • Tumor Cells, Cultured

Substances

  • DNA, Antisense
  • RNA, Antisense
  • Globins